Savvy Stock Picks

Dendreon Corporation (NASDAQ:DNDN) percentage change fell -0.73%, currently trading at $36.89 and its overall traded volume is 654,258.00 shares while reporting at 11:00 AM on Tuesday, against its average volume of 2.64M. DNDN opened the day at $36.93, it made an intraday low of $36.60 and an intraday high of $37.32. The 52-week range of the stock is $25.78-$57.67. The market capitalization of the company stands at 5.32B and it has 144.33M outstanding shares.Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Its advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic, castrate-resistant, (also known as androgen-independent or hormone-refractory) prostate cancer. Its lead product candidate, Provenge (sipuleucel-T), is designed to target the prostate cancer antigen prostatic acid phosphatase (PAP), an antigen that is expressed in more than 90 % of all prostate cancers. The antigen target for Neuvengetm (lapuleucel-T), its active immunotherapy candidate in development for the treatment of bladder, breast, ovarian and other solid tumors, is a HER2/neu.

Life Technologies Corp. (NASDAQ:LIFE) gained 0.09%, currently trading at $55.30 and its overall traded volume is 655,847.00 shares while reporting at 11:00 AM on Tuesday, against its average volume of 1.81M. LIFE opened at $55.32 and is trading within the range of $55.11-$55.78. The 52-week range of the stock is $41.10-$57.25. The market capitalization of the company stands at 10.33B and it has 186.73M outstanding shares.Life Technologies Corporation (Life Technologies) is a biotechnology tools company. The Company delivers a range of products and services, including systems, instruments, reagents, software, and custom services. Its range of products includes technologies for capillary electrophoresis based sequencing, sequencing, Polymerase Chain Reaction (PCR), sample preparation, cell culture, ribonucleic acid (RNA) interference analysis, functional genomics research, proteomics and cell biology applications, as well as clinical diagnostic applications, forensics, animal, food, pharmaceutical and water testing analysis. As of the year end December 31, 2009, the Company divided products and services into four divisions: Molecular Biology Systems (MBS), Cell Systems (CS), Genetic Systems (GS) and Mass Spectrometry. In February 2010, the Company completed the sale of mass spectrometry business to Danaher Corporation. In May 2010, the Company acquired 59% interest in Geneart AG.

Joy Global Inc. (NASDAQ:JOYG) went up 1.92%, currently trading at $92.93 and its overall traded volume is 655,869.00 shares while reporting at 11:00 AM on Tuesday, the stock has average daily volume of 1.43M shares. JOYG shares were trading within the range of $91.04-$93.04 while its opening price is $91.04. The 52-week range of the stock is $42.45-$93.04. JOYG’s market capitalization is 9.63B and it has 103.62M outstanding shares.Joy Global Inc. is a manufacturer and servicer of mining equipment for the extraction of coal and other minerals, and ores. The Company’s equipment is used in mining regions throughout the world to mine coal, copper, iron ore, oil sands and other minerals. Its underground mining machinery segment (Joy Mining Machinery or Joy) is a manufacturer of underground mining equipment for the extraction of coal and other bedded minerals and offers service locations near mining regions worldwide. Its surface mining equipment segment (P&H Mining Equipment or P&H) is a producer of surface mining equipment for the extraction of ores and minerals and provides operational support for many types of equipment used in surface mining. During the fiscal year ended October 29, 2010 (fiscal 2010), the Company completed the integration of Continental Crushing and Conveying by combining this segment into its Underground Mining Machinery and Surface Mining Equipment segments.

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) percentage change surged 0.46%, currently trading at $1.77 and its overall traded volume is 647,605.00 shares while reporting at 11:00 AM on Tuesday, the stock has average daily volume of 1.58M shares. BPAX opened at $1.79 and is trading within the range of $1.75-$1.84. The 52-week range of the stock is $1.29-$2.50. The market capitalization of the company stands at 125.88M and it has 71.19M outstanding shares.BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company’s products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

XOMA Limited (NASDAQ:XOMA) percentage change grew 2.62%, currently trading at $5.94 and its overall traded volume is 858,211.00 shares while reporting at 11:00 AM on Tuesday, with the total traded volume of 7.79M shares. XOMA opened the day at $5.80, it made an intraday low of $5.70 and an intraday high of $6.11. The 52-week range of the stock is $2.24-$12.60. The market capitalization of the company stands at 129.52M and it has 21.80M outstanding shares.XOMA Ltd. (XOMA) is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company’s product development pipeline includes XOMA 052, an anti-interleukin-1 beta (IL-1 beta) antibody, XOMA 3AB, a biodefense anti-botulism antibody candidate, and preclinical antibody discovery programs in several indications. XOMA have an integrated product development platform, extending from preclinical science to development and manufacturing. The Company’s technologies have contributed to the success of marketed antibody products, including LUCENTIS (ranibizumab injection) for wet age-related macular degeneration and CIMZIA (certolizumab pegol) for rheumatoid arthritis and Crohn’s disease.